Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 3;13(1):131.
doi: 10.3390/cancers13010131.

Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer

Antonio Lopez-Beltran  1 , Alessia Cimadamore  2 , Ana Blanca  3 , Francesco Massari  4 , Nuno Vau  5 , Marina Scarpelli  2 , Liang Cheng  6 , Rodolfo Montironi  2
Affiliations
Review

Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer

Antonio Lopez-Beltran et al. Cancers (Basel). .

Abstract

A number of immune checkpoint inhibitors (ICIs) have been approved as first-line therapy in case of cisplatin-ineligible patients or as second-line therapy for patients with metastatic urothelial carcinoma (mUC) of the bladder. About 30% of patients with mUC will respond to ICIs immunotherapy. Programmed death-ligand 1 (PD-L1) expression detected by immunohistochemistry seems to predict response to immune checkpoint inhibitors in patients with mUC as supported by the objective response rate (ORR) and overall survival (OS) associated with the response observed in most clinical trials. Pembrolizumab, an anti-PD-1 antibody, demonstrated better OS respective to chemotherapy in a randomized phase 3 study for second-line treatment of mUC. Nivolumab, a PD-1 antibody, also demonstrated an OS benefit when compared to controls. Atezolizumab, Durvalumab, and Avelumab antibodies targeting PD-L1 have also received approval as second-line treatments for mUC with durable response for more than 1 year in selected patients. Atezolizumab and Pembrolizumab also received approval for first-line treatment of patients that are ineligible for cisplatin. A focus on the utility of ICIs in the adjuvant or neoadjuvant setting, or as combination with chemotherapy, is the basis of some ongoing trials. The identification of a clinically useful biomarker, single or in association, to determine the optimal ICIs treatment for patients with mUC is very much needed as emphasized by the current literature. In this review, we examined relevant clinical trial results with ICIs in patients with mUC alone or as part of drug combinations; emphasis is also placed on the adjuvant and neoadjuvant setting. The current landscape of selected biomarkers of response to ICIs including anti-PD-L1 immunohistochemistry is also briefly reviewed.

Keywords: Atezolizumab; Avelumab; Durvalumab; Nivolumab; PD-1; PD-L1; Pembrolizumab; biomarker; bladder cancer; immune checkpoint inhibitor; immunotherapy; tumor mutation burden; urothelium; variant histology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Programmed death-ligand 1 (PD-L1) membranous immunostaining in high-grade urothelial carcinoma (22C3 antibody) (200×).
See this image and copyright information in PMC

References

    1. Antoni S., Ferlay J., Soerjomataram I., Znaor A., Jemal A., Bray F. Bladder cancer incidence and mortality: A global overview and recent trends. Eur. Urol. 2017;71:96–108. doi: 10.1016/j.eururo.2016.06.010. - DOI - PubMed
    1. Polo S.H., Gonzalez del Alba A., Perez-Valderrama B., Villa Guzman J.C., Climent M.A., Lainez N., Font A., Duran I., Mellado B., Castellano D., et al. Vinflunine maintenance therapy versus best supportive care after platinum combination in advanced bladder cancer: A phase II, randomized, open label, study (MAJA study, SOGUG 2011-02)—Interim analysis on safety. J. Clin. Oncol. 2014;32:359. doi: 10.1200/jco.2014.32.4_suppl.359. - DOI - PubMed
    1. Bellmunt J., Théodore C., Demkov T., Komyakov B., Sengelov L., Daugaard G., Caty A., Carles J., Jagiello-Gruszfeld A., Karyakin O., et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol. 2009;27:4454–4461. doi: 10.1200/JCO.2008.20.5534. - DOI - PubMed
    1. Oing C., Rink M., Oechsle K., Seidel C., Von Amsberg G., Bokemeyer C. Second line chemotherapy for advanced and metastatic urothelial carcinoma: Vinflunine and beyond-a comprehensive review of the current Literature. J. Urol. 2016;195:254–263. doi: 10.1016/j.juro.2015.06.115. - DOI - PubMed
    1. Bellmunt J., Powles T., Vogelzang N.J. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. Cancer Treat. Rev. 2017;54:58–67. doi: 10.1016/j.ctrv.2017.01.007. - DOI - PubMed